Freely Filtered, a NephJC Podcast

FF96 MAJESTY, or Mentor Two

Freely Filtered, a NephJC Podcast

Show Notes

The Filtrate Joel Topf @kidney_boy Swapnil Hiremath @hswapnil.medsky.social Natalie Freidin Program director at Medical University of South Carolina AC @medpeedskidneys.bsky.social Special Guests Fernando Fervenza Professor of Medicine, The Mayo Clinic

Editing Vip Vergues The Kidney Connection written and performed by Timothy Yau

Show Notes MENTOR NephJC | NEJM | Freely Filtered episode 7 PLA2r in 2009 M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy NEJM MAJESTY NephJC | NEJM Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy Giuseppe Remuzzi discovers rituximab works in primary membranous. Rituximab for idiopathic membranous nephropathy The Lancet 2002 Fervenza’s 15-person study of Rituximab treatment of idiopathic membranous nephropathy Kidney International 2008. Larry Beck’s NEJM PLA2r study M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy NEJM 2009 2011 (not 2010) JASN paper where using banked serum from two prior rituximab studies in membranous nephropathy, Beck and Fervenza showed that declines in anti-PLA2R antibodies preceded reductions in proteinuria and predicted subsequent clinical remission, establishing the concept that immunologic remission precedes clinical remission. Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy PubMed The National Institute of Animal Health…a Fervenza fiction Robert A. Star, M.D. NIH Daniel C. Cattran, M.D. NephCure

Tubular Secretions Swap do not go to see Mandalorian and Grogu or Supergirl AC doing nothing Natalie The Wealth Ladder by Nick Maggiulli (amazon) Fernando South Portugal and GlomCon Hawaii Joel The Boundary Waters Canoe Area

More from Freely Filtered, a NephJC Podcast

Oct 15, 2026

The Filtrate Joel Topf @kidney_boy Swapnil Hiremath @hswapnil.medsky.social Anna Gaddy @annagaddy.bsky.social Natalie Freidin Program director at Medical University of South Carolina Special Guests Brendon “Brendo” Neuen The first Five-Time guest on Freely Filtered. Nephrologist and Director, Kidney Trials, Royal North Shore Hospital. Associate Professor of Medicine at the George Institute

Sep 27, 2026

Bypass surgery continues to be the laboratory where we test the most innovative ideas on the prevention of AKI The Filtrate Joel Topf @kidney_boy Swapnil Hiremath @hswapnil.medsky.social Vipin Varghese Sophia Ambruso Special Guests Rahul Ganatra Deputy Editor NEJM Clinician. https://clinician.nejm.org/editors/AU3406 Jay Koyner Professor of Medicine, University of Chicago. https://www.uchicagomedicine.org/find-a-physician/physician/jay-koyner

Aug 23, 2026

The Filtrate Joel Topf@kidney_boy Vipin [email protected] Nayan Arora @captainchloride Special Guests David Goldfarb Professor of Medicine, NYU (COI) Megan Prochaska Assistant professor of medicine at University of Chicago John Asplin Medical Director Consultant LithoLink (Twitter)

Jul 17, 2026

The Filtrate Joel Topf kidneyboy.bsky.social Swapnil Hiremath @hswapnil.medsky.social Natalie Freidin Program director at Medical University of South Carolina Sophia Ambruso @sophia_kidney AC @medpeedskidneys.bsky.social

Jun 30, 2026

The Filtrate Joel Topf kidneyboy.bsky.social Swapnil Hiremath @hswapnil.medsky.social Pedro Teixeira @nephcrit.bsky.social

See all episodes →